MedTrace Logo

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

NCT05838703 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-15

No results posted yet for this study

Summary

The purpose of this study is to determine if tiotropium Respimat will result in better ventilation distribution of the lung in COPD participants quantified by hyperpolarized XeMRI. This study is designed to simulate the real-life clinical setting where patients receive one-time instruction on the inhaler use.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

tiotropium bromide inhalation powder (Spiriva HandiHaler)

Spiriva HandiHaler is a COPD medication that is available for use.

DRUG

tiotropium bromide (Spiriva Respimat)

Spiriva Respimat is a COPD medication that is available for use.

DRUG

Hyperpolarized 129XeMRI

Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-05-01
Completion
2024-05-01
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05838703 on ClinicalTrials.gov